Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 4/20 | 0.70 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.69 |
| ▸ | BRAF | P15056 | 7/20 | 0.64 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.63 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.63 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4303736 | 0.93 | BRAF (0.62) | MAPK13MAPK14BRAFPTK2MAPK12 | |
| SCHEMBL4302985 | 0.86 | MAPK14 (0.64) | MAPK13MAPK14BRAFPTK2MAPK12 | |
| SCHEMBL12540713 | 0.85 | MAPK13 (0.62) | MAPK13MAPK14BRAFPTK2MAPK12 | |
| SCHEMBL16866510 | 0.84 | MAPK13 (0.83) | MAPK13MAPK14BRAFPTK2MAPK12 | |
| SCHEMBL4303700 | 0.83 | FLT3 (0.60) | MAPK13MAPK14BRAFMAPK12MAPK11 | |
| SCHEMBL3181604 | 0.83 | KDR (0.60) | MAPK14BRAF | |
| SCHEMBL13741201 | 0.83 | MAPK14 (1.00) | MAPK13MAPK14PTK2MAPK12MAPK11 | |
| SCHEMBL4307838 | 0.83 | MAPK13 (0.59) | MAPK13MAPK14BRAFPTK2MAPK12 | |
| SCHEMBL16870189 | 0.83 | MAPK13 (1.00) | MAPK13MAPK14BRAFPTK2MAPK12 | |
| SCHEMBL13234636 | 0.82 | MAPK14 (0.84) | MAPK13MAPK14BRAFPTK2MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131437-A1 | DISUBSTITUTED UREAS AS KINASE INHIBITORS | CORIUM INTERNATIONAL, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| EP-1838700-A2 | DISUBSTITUTED UREAS AS KINASE INHIBITORS | Novartis AG (CH) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006072589-A2 | DISUBSTITUTED UREAS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131437-A1 | DISUBSTITUTED UREAS AS KINASE INHIBITORS | UCK2, ULK2, MAP3K1 | MAPK13 103/4885MAPK14 133/4885BRAF 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.